Table I.
Caveolin-1 expression in patient archival samples.
| Poorly differentiated | Moderately/well differentiated | |||
|---|---|---|---|---|
|
| ||||
| Case no. | Cav-1 expression
|
Cav-1 expression
|
||
| Cancer | Stroma | Cancer | Stroma | |
| 1 | 3 | 1 | 1 | 3 |
| 2 | 2 | 2 | 0 | 2 |
| 3 | No PD areas | 2 | 3 | |
| 4 | No PD areas | 2 | 1 but scarce stroma | |
| 5 | No PD areas | 1 | 3 | |
| 6 | 1 | 3 | 0 | 3 |
| 7 | 3 | 2 | 0 | 1 but scarce stroma |
| 8 | 3 | 1 | 1 | 3 |
| 9 | 2 | 2 | 1 | 3 |
| 10 | 3 | 1 | 1 | 3 |
| 11 | No PD areas | 0 | 3 | |
Caveolin-1 expression in cancer cells and stroma in well and poorly differentiated areas of pancreatic cancer in 11 archival samples. For details please see the Materials and methods, immunohistochemistry. Cav-1 staining was graded as follows: 0, negative; 1, weak and/or focal (<10%); 2, moderate or strong (10-50%); 3, moderate or strong >50%. Cav-1, caveolin-1, PD, poorly differentiated.